Although tumorous PD‐L1 expression is well known as a conventional biomarker of the ICI therapeutic response, there is no widely accepted optimal biomarker to predict the efficacy of ICI, because ICI response and survival outcomes show heterogeneity in NSCLC patients receiving cancer immunotherapy, regardless of PD‐L1 expression level. The gene discussed is CD274; the disease is non-small cell lung carcinoma.